ERYTHRASMA

Background
Erythrasma is a chronic superficial infection of the intertriginous areas of the skin. The incriminated organism
is Corynebacterium minutissimum, which usually is present as a normal human skin inhabitant. In
1996, Corynebacterium afermentans was reported in one case.[1]

Pathophysiology
Corynebacteria invade the upper third of the stratum corneum; under favorable conditions such as heat and humidity,
these organisms proliferate. The stratum corneum is thickened. The organisms that cause erythrasma are seen in the
intercellular spaces as well as within cells, dissolving keratin fibrils. The coral-red fluorescence of scales seen under
Wood light is secondary to the production of porphyrin by these diphtheroids.

Epidemiology
Frequency
International
The incidence of erythrasma is reported to be around 4%. This infection is observed all over the world; the widespread
form is found more frequently in the subtropical and tropical areas than in other parts of the world. [2]
In a recent study conducted in Turkey, the rate of erythrasma was found to be 46.7% among 122 patients with
interdigital foot lesions.[3]

Mortality/Morbidity
Erythrasma is usually a benign condition. However, it may become widespread and invasive in predisposed and
immunocompromised individuals; this is very rare in immunocompetent hosts. In such individuals, this organism has
caused infections other than erythrasma. These include abscess formation (3 cases), [4]intravascular catheterrelated
infections (2 cases),[5] primary bacteremia (3 cases), peritoneal catheterrelated infections (2 cases), [5, 6] endocarditis (2
cases),[7, 8] pyelonephritis (2 cases),[9, 10] cellulitis (1 case),[11] endophthalmitis (1 case),[12] arteriovenous fistula infection (1
case), cutaneous granuloma (1 case),[13] and meningitis (1 case).[14]

Race
The incidence of erythrasma is higher in black patients.

Sex
Both sexes are equally affected by erythrasma; however, the crural form of erythrasma is more common in men. A
2008 study found that interdigital erythrasma was more common in women (83% of 24 patients). [15]

Age
The incidence of erythrasma increases with age, but no age group is immune to the disease. The youngest patient
reported to have erythrasma is a 1-year-old infant.

History

Dark discoloration associated with erythrasma is usually limited to body folds that are naturally moist and occluded.
Infection commonly is asymptomatic, but it can be pruritic. The duration of erythrasma ranges from months to years.
Widespread involvement of trunk and limbs is possible.
Immunosuppressed patients with erythrasma and the risk of complications are of special concern. Evaluate and treat
possible concomitant infection. Suspect diabetes in recurrent erythrasma. Address and modify risk factors for
successful treatment

Physical
The typical appearance of erythrasma is well-demarcated, brown-red macular patches. The skin has a wrinkled
appearance with fine scales (see the image below).

Lichenification and hyperpigmentation are common. The skin occasionally has a wrinkled
appearance with scales. KOH test results are negative. Courtesy of Michael Bryan, MD.

Infection commonly is located on the inner thighs, crural region, scrotum, and toe webs. The axillae, submammary
area, periumbilical region, and intergluteal folds are less commonly involved in erythrasma. Toe web lesions appear as
maceration, with the fourth interdigital space most frequently affected. [15]
Due to the association of erythrasma with other corynebacterial skin infections such as pitted keratolysis and
trichomycosis axillaris, all body folds and feet should be screened.

Causes

C minutissimum, a member of the normal skin flora, is the causative agent of erythrasma. The bacterium is a
lipophilic, gram-positive, nonspore-forming, aerobic, and catalase-positive diphtheroid. C minutissimum ferments
glucose, dextrose, sucrose, maltose, and mannitol.
Predisposing factors for erythrasma include the following:
Excessive sweating/hyperhidrosis
Delicate cutaneous barrier
Obesity
Diabetes mellitus
Warm climate
Poor hygiene
Advanced age
Other immunocompromised states

Differential Diagnoses

Acanthosis Nigricans
Candidiasis, Cutaneous
Contact Dermatitis, Allergic
Contact Dermatitis, Irritant
Intertrigo
Psoriasis, Plaque
Seborrheic Dermatitis
Tinea Corporis
Tinea Cruris
Tinea Pedis

Laboratory Studies

Wood light examination of erythrasma lesions reveals coral-red fluorescence of lesions. Results may be
negative if the patient bathed prior to presentation. [22]Note the image below. The cause of this color
fluorescence has been attributed to excess coproporphyrin III synthesis by these organisms, which
accumulates in cutaneous tissue and emits a coral-red fluorescence when exposed to a Wood light. [23, 23]

Under Wood lamp examination, the porphyrins produced by the bacteria fluoresce with a
coral pink color. A small focus is visible on this photo. If the patient recently has bathed, the pigment may be washed away. In
suspicious cases, a repeat examination the following day may be necessary. Courtesy of Michael Bryan, MD.

Gram staining reveals of erythrasma lesions gram-positive filamentous rods. In culture media composed of
20% fetal bovine serum, 2% agar, 78% tissue culture medium #199, and 0.05% tris, the organisms grow as
nonhemolytic, 1- to 1.5-mm smooth colonies. Methylene blue stain may be used to highlight both the fungal
spores of pityriasis versicolor and the curved or club-shaped bacterial rods of C minutissimum, the causative
agent of erythrasma, in case both organisms coexist. [17]
Next Section: Histologic Findings

Histologic Findings
The diphtheroid bacteria that cause erythrasma are present in the horny layer as rods and filaments. [24]

Medical Care
Photodynamic therapy using red light (broadband, peak at 635 nm) has been reported to clear erythrasma in 23% of
13 patients and to improve erythrasma in the remaining patients. [25]

Medication Summary
The goals of pharmacotherapy for erythrasma are to reduce morbidity, eradicate the infection, and prevent
complications.

Anti-infectives
Class Summary
Antibacterial and/or antifungal agents are used to eradicate C minutissimum and possible concomitant infection.
Erythromycin is the DOC. Infection may be treated with topical and/or oral agents. Therapy must be comprehensive
and cover all likely pathogens in the context of this clinical setting. C minutissimum is generally susceptible to
penicillins, first-generation cephalosporins, erythromycin, clindamycin, ciprofloxacin, tetracycline, and vancomycin.
However, multiresistant strains have been isolated.[26, 27, 28, 29]
In a recent susceptibility study of 40 patients, several antibiotics were tested, including penicillin G, ampicillin, cefaclor,
amoxicillin-clavulanate, ampicillin-sulbactam, tetracycline, erythromycin, ofloxacin, fusidic acid, levofloxacin, and
azithromycin. The study revealed statistically significant resistance to erythromycin, azithromycin, penicillin, and
ampicillin. Significant susceptibility was statistically found to amoxicillin-clavulanate, cefaclor, and fusidic acid. [30]
In a large double-blind, placebo-controlled, randomized trial, 151 patients older than 18 years were randomized into 5
groups and were given either erythromycin, single-dose clarithromycin, topical fusidic acid, placebo cream, or placebo
tablets. Fusidic acid cream was significantly more effective than other therapies. Additionally, the group who received
clarithromycin did better at 48 hours than did the group that received erythromycin. However, there was no statistical
difference on day 7 and day 14.[31]
Because culture and antibiogram are not performed routinely in daily clinical practice, the recommended initial topical
treatment is fusidic acid cream. If this drug is not available, then topical erythromycin solution may be an alternative. In
cases of topical treatment failure, erythromycin, single-dose clarithromycin, or amoxicillin-clavulanate should be
chosen for the systemic treatment.[30]

View full drug information

Erythromycin (E.E.S., E-Mycin, Ery-Tab)

DOC that inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNAdependent protein synthesis to arrest.
In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily
dose may be taken q12h. For more severe infections, double the dose.
View full drug information

Clarithromycin (Biaxin)
Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent
protein synthesis to arrest.

Fusidic acid (Zeta)

Topical antibacterial that inhibits bacterial protein synthesis, causing bacterial death.
Use 2% cream.
View full drug information

Miconazole topical (Femazole, Lotrimin, Monistat)

Damages fungal cell wall membrane by inhibiting biosynthesis of ergosterol. Membrane permeability is increased,
causing nutrients to leak out and resulting in fungal cell death.
Lotion is preferred in intertriginous areas. If cream is used, apply sparingly to avoid maceration effects.
Use 2% cream.

Benzoic acid 6%, salicylic acid 3% (Whitfield's ointment)

Treats infection and inflammation associated with erythrasma.

Clindamycin (Cleocin)
Has a bacteriostatic effect; interferes with bacterial protein synthesis similarly to erythromycin and chloramphenicol by
binding to 50S subunit of bacterial ribosome.
View full drug information

Tetracycline (Achromycin)
Inhibits cell growth by inhibiting mRNA translation. Binds to 16S part of 30S ribosomal subunit and prevents aminoacyl tRNA from binding to A site of ribosome. Binding is reversible in nature.

Complications

Note the following possible complications:

Fatal septicemia in immunocompromised patients with erythrasma
Infective endocarditis in valvular heart disease patients with erythrasma
Postsurgical wound infection in erythrasma patients

Prognosis
The prognosis for erythrasma is excellent; however, the condition tends to recur if the predisposing factors are not
eliminated.

Patient Education
Patients with erythrasma should be instructed to keep the area dry.

References
1. Dellion S, Morel P, Vignon-Pennamen D, Felten A. Erythrasma owing to an unusual pathogen. Arch Dermatol.
Jun 1996;132(6):716-7. [Medline].
2. Sarkany I, Taplin D, Blank H. Incidence and bacteriology of erythrasma. Arch Dermatol. May 1962;85:57882. [Medline].
3. Inci M, Serarslan G, Ozer B, et al. The prevalence of interdigital erythrasma in southern region of Turkey. J
Eur Acad Dermatol Venereol. Oct 7 2011;[Medline].
4. Bandera A, Gori A, Rossi MC, et al. A case of costochondral abscess due to Corynebacterium minutissimum
in an HIV-infected patient. J Infect. Jul 2000;41(1):103-5. [Medline].
5. Van Bosterhaut B, Cuvelier R, Serruys E, Pouthier F, Wauters G. Three cases of opportunistic infection
caused by propionic acid producing Corynebacterium minutissimum. Eur J Clin Microbiol Infect Dis. Jul
1992;11(7):628-31. [Medline].
6. Fernandez Giron F, Saavedra Martin JM, Bentez Sanchez M, Fernandez Mora F, Rodriguez Gomez E.
Corynebacterium minutissimum peritonitis in a CAPD patient. Perit Dial Int. May-Jun 1998;18(3):345-6.
[Medline].
7. Aperis G, Moyssakis I. Corynebacterium minutissimum endocarditis: a case report and review. J Infect. Feb
2007;54(2):e79-81. [Medline].
8. Herschorn BJ, Brucker AJ. Embolic retinopathy due to Corynebacterium minutissimum endocarditis. Br J
Ophthalmol. Jan 1985;69(1):29-31. [Medline].
9. Ahmad NM, Ahmad KM. Corynebacterium minutissimum pyelonephritis with associated bacteraemia: a case
report and review of literature. J Infect. Dec 2005;51(5):e299-303. [Medline].
10. Craig J, Grigor W, Doyle B, Arnold D. Pyelonephritis caused by Corynebacterium minutissimum. Pediatr Infect
Dis J. Dec 1994;13(12):1151-2. [Medline].
11. Granok AB, Benjamin P, Garrett LS. Corynebacterium minutissimum bacteremia in an immunocompetent host
with cellulitis. Clin Infect Dis. Aug 15 2002;35(4):e40-2. [Medline].
12. Arsan AK, Sizmaz S, Ozkan SB, Duman S. Corynebacterium minutissimum endophthalmitis: management
with antibiotic irrigation of the capsular bag. Int Ophthalmol. 1995-1996;19(5):313-6.[Medline].
13. Santos-Juanes J, Galache C, Martinez-Cordero A, et al. Cutaneous granulomas caused by corynebacterium
minutissimum in an HIV-infected man. J Eur Acad Dermatol Venereol. Nov 2002;16(6):643-5. [Medline].
14. Dalal A, Likhi R. Corynebacterium minutissimum bacteremia and meningitis: a case report and review of
literature. J Infect. Jan 2008;56(1):77-9. [Medline].
15. Morales-Trujillo ML, Arenas R, Arroyo S. [Interdigital erythrasma: clinical, epidemiologic, and microbiologic
findings]. Actas Dermosifiliogr. Jul-Aug 2008;99(6):469-73. [Medline].
16. Aste N, Pau M, Aste N. Pityriasis versicolor on the groin mimicking erythrasma. Mycoses. Jun 2004;47(56):249-51. [Medline].
17. Karakatsanis G, Vakirlis E, Kastoridou C, Devliotou-Panagiotidou D. Coexistence of pityriasis versicolor and
erythrasma. Mycoses. Aug 2004;47(7):343-5. [Medline].
18. Bowyer A, McColl I. Erythrasma and pruritus ani. Acta Derm Venereol. 1971;51(6):444-7. [Medline].
19. Marinella MA. Erythrasma and seborrheic dermatitis of the groin. Am Fam Physician. Nov 15
1995;52(7):2012. [Medline].
20. Rho NK, Kim BJ. A corynebacterial triad: Prevalence of erythrasma and trichomycosis axillaris in soldiers with
pitted keratolysis. J Am Acad Dermatol. Feb 2008;58(2 Suppl):S57-8. [Medline].
21. Finch J. Case of trichomycosis axillaris and erythrasma. J Drugs Dermatol. Dec 2011;10(12):1472-3.[Medline].
22. Mattox TF, Rutgers J, Yoshimori RN, Bhatia NN. Nonfluorescent erythrasma of the vulva. Obstet Gynecol.
May 1993;81(5 (Pt 2)):862-4. [Medline].
23. Yasuma A, Ochiai T, Azuma M, et al. Exogenous coproporphyrin III production by Corynebacterium
aurimucosum and Microbacterium oxydans in erythrasma lesions. J Med Microbiol. Jul 2011;60:1038-42.
[Medline].

24. Montes LF, Black SH, McBride ME. Bacterial invasion of the stratum corneum in erythrasma. I. Ultrastructural
evidence for a keratolytic action experted by Corynebacterium minutissimum. J Invest Dermatol. Nov
1967;49(5):474-85. [Medline].
25. Darras-Vercambre S, Carpentier O, Vincent P, Bonnevalle A, Thomas P. Photodynamic action of red light for
treatment of erythrasma: preliminary results. Photodermatol Photoimmunol Photomed. Jun 2006;22(3):1536. [Medline].
26. Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the
topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol. Sep
1973;89(3):297-303. [Medline].
27. Hamann K, Thorn P. Systemic or local treatment of erythrasma? A comparison between erythromycin tablets
and Fucidin cream in general practice. Scand J Prim Health Care. Mar 1991;9(1):35-9. [Medline].
28. Holdiness MR. Management of cutaneous erythrasma. Drugs. 2002;62(8):1131-41. [Medline].
29. Wharton JR, Wilson PL, Kincannon JM. Erythrasma treated with single-dose clarithromycin. Arch Dermatol.
Jun 1998;134(6):671-2. [Medline].
30. Turk BG, Turkmen M, Aytimur D. Antibiotic susceptibility of Corynebacterium minutissimum isolated from
lesions of Turkish patients with erythrasma. J Am Acad Dermatol. Dec 2011;65(6):1230-1. [Medline].
31. Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose
clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat. Sep 18 2011;
[Medline].